We have previously developed and validated a self-administered questionnaire, modelled after the Systemic Lupus International Collaborating Clinics Damage Index (SDI), the Lupus Damage Index Questionnaire (LDIQ), which may allow the ascertainment of this construct in systemic lupus erythematosus (SLE) patients followed in the community and thus expand observations made about damage. We have now translated, back-translated and adapted the LDIQ to Spanish, Portuguese and French and applied it to patients followed at academic and non-academic centres in North and South America, Portugal and Spain while their physicians scored the SDI. A total of 887 patients (659 Spanish-speaking, 140 Portuguese-speaking and 80 French-speaking patients) and 40 physicians participated. Overall, patients scored all LDIQ versions higher than their physicians (total score and all domains). Infrequent manifestations had less optimal clinimetric properties but overall agreement was more than 95% for the majority of items. Higher correlations were observed among the Spanish-speaking patients than the Portuguese-speaking and Frenchspeaking patients; further adjustments may be needed before the Portuguese and French versions of the LDIQ are applied in community-based studies. The relationship between the LDIQ and other outcome parameters is currently being investigated in a different patient sample. Lupus 
Introduction
The Systemic Lupus International Collaborating Clinics (SLICC) Damage Index (SDI) was developed in 1996 by SLICC investigators in an effort to uniformly quantify the impact of organ damage in systemic lupus erythematosus (SLE). 1, 2 This avoided the pitfalls of the parallel development of several instruments to assess the same construct as this had already occurred with disease activity for which instruments were developed in North America and Europe. [3] [4] [5] [6] [7] To date, the SDI has been used primarily for studies at academic centres rather than in the community, and thus the current literature concerning organ damage in SLE may not be reflective of the general SLE population. [8] [9] [10] [11] [12] Furthermore, like all physicianscompleted instruments, the SDI is difficult to apply in longitudinal observational studies in populationbased samples and/or in long-term assessments in clinical trials.
In an effort to ascertain damage in SLE in an unselected population-based sample, we have developed and validated a self-administered questionnaire, the Lupus Damage Index Questionnaire (LDIQ). 13 This instrument has recently been validated using both academic and non-academic practices in North America and the United Kingdom. 14 The LDIQ has now been translated into Spanish, Portuguese and French, and it has been applied to Spanish-speaking patients in Spain, the USA and Latin America, to Portuguesespeaking patients in Portugal and Brazil and to French-Canadian patients. The results of this exercise are hereby being reported.
Methods
This study was approved by the Ethics Committee at all participating sites and was conducted according to the Declaration of Helsinki for research in humans.
The English version of the LDIQ was translated, back-translated and culturally adapted to Spanish, Portuguese and French using standard methodology. 15 Language variations and cultural differences between Brazil and Portugal required two somewhat different Portuguese versions of the questionnaire as the Brazilian translation was believed not to be adequate by Portuguese investigators; however, that was not the case for the Spanish questionnaire which after being applied on a pilot basis to few participants in the 31 different Spanish-speaking countries and reviewed by all investigators was felt to be culturally and linguistically appropriate in all (Appendices 1-4; Appendices 1-6 available online at http://lup.sagepub.com). Next, GLADEL centres (Grupo Latino Americano del Estudio de Lupus or Latin America Group for the Study of Lupus) 16 and other centres in Latin America, the USA, Canada, Spain and Portugal were invited to participate in this study by enrolling consecutive SLE patients attending their practices.
Patients were asked to complete the LDIQ and physicians were asked to complete the SDI independently. SDI and LDIQ total and domain scores were computed and compared using the Student's t-test and Pearson's correlation coefficients. Using the SDI as the gold standard, the sensitivity, specificity, positive and negative predictive values and overall agreement were calculated for all SDI domain items. For these analyses, the Stata, version 10.1 statistical program (StataCorp, College Station, Texas, USA) was used.
Results
A total of 887 SLE patients and 40 physicians participated in this study; of them, 659 patients completed the Spanish (611 in Latin America, 30 in the United States and 18 in Spain), 140 the Portuguese (122 in Brazil and 18 in Portugal) and 88 the French (all in Canada) versions of the LDIQ. The majority of the patients were women (91%), of middle age (38.3 years) with about 10 years of disease duration and 12 years of education. As expected, the majority of the patients were of European and Amerindian and, to a lesser extent, of African ancestry and ethnic background, depending on the location of the participating centres (Table 1) . A total of 40 physicians (men 64%, mean age 48 years, mean number of years in practice 17, nearly all with formal rheumatology training and experience in the application of the SDI at 33 centres participated in the exercise (Table 1) . Twenty-two were GLADEL centres; the others were located in Latin America (n = 2), the United States (n = 5), Canada (n = 2) and one each in Spain and Portugal. The centres in the United States, Canada, Spain and Portugal were all academic, whereas in Latin America there were both academic and non-academic. The majority of the patients completed the LDIQ (87%) before seeing their physicians in the clinic. Physicians completed the SDI by interview and physical examination although access to medical records was allowed. Table 2 shows the SDI and LDIQ mean (standard deviation [SD] ), SDI total and domain scores for all physicians and for the Spanish-speaking, Portuguesespeaking and French-speaking patients, separately and combined. As noted, patients, overall, tended to The comparisons were all significant at P < 0.01. Table 3 depicts the correlations between the SDI and the LDIQ scores for the damage index overall and for its domains. These correlations were highest for the ocular domain across the three groups and were overall higher for the Spanish questionnaires than for the French and for the Portuguese. In Appendix 5 (Appendices 1-6 available online at http://lup.sagepub.com), the sensitivity, specificity, positive and negative predictive values and overall agreement (percent of patients correctly classified by patients and physicians) for all items on the different domains of the SDI and LDIQ are shown. Infrequent manifestations had less optimal clinimetric properties but the overall agreement was more than 95% for the majority of the items. Of interest, similar results were obtained when the data were examined by individual investigator and compared between those in academic and non-academic centres (data not shown).
Discussion
We have now translated, adapted and validated Spanish, Portuguese and French versions of the LDIQ, a self-administered questionnaire modelled after the SDI. Similar to our initial preliminary experience with the English version of the LDIQ 13 and the most recent assessment in a larger sample, 14 we have shown that patients consistently score higher than their physicians in the different items and domains that constitute this index. This held true across Spanish-speaking patients in Latin America, the United States and Spain, Portuguese-speaking patients in Brazil and Portugal and French-Canadian patients. One caveat is that our studies, so far, have been cross-sectional, and the properties of the LDIQ may differ in the context of longitudinal observational studies. The best correlations between patients' and physicians' scores were observed for the Spanish-speaking patients (0.52 for the pulmonary domain and 0.76 for the ocular domain and 0.68 for the total score), whereas there was significant variability for the French-speaking and the Portuguese-speaking patients, which may be due to the smaller sample size of these samples compared to the Spanish sample or due to the lack of understanding of the questions as worded, which could also relate to a lower level of education among the Portuguese-speaking patients, particularly those in Brazil (10.5 years vs 12.0 years for the Spanish-speaking patients). However, the level of education cannot be the sole reason as the French-speaking patients were the ones with the highest level of education (~14 years). Thus, further adjustments to some items of the Portuguese and French versions are needed before they are used in community-based longitudinal observational studies or clinical trials. Nevertheless, the large majority of the items were correctly classified by the patients and the physicians, with the exception of those which occurred infrequently. In all the three cases, however, the highest correlations were obtained for the ocular domain of the SDI, whereas the lowest were for the pulmonary domain for the Spanish-speaking patients and for the cardiovascular domain for the Frenchspeaking and Portuguese-speaking patients. In summary, our study suggests that both the original SDI and the self-administered LDIQ reflect the same domains although the two instruments appear to measure these domains with different types and degrees of error; however, adjustments are needed to the Portuguese and French versions of the questionnaires. Further studies to ascertain the relationship between this questionnaire and other outcome measurements are in progress. Longitudinal assessments, likewise, may provide additional information on the value of this instrument. If proven reliable in the longitudinal setting, the LDIQ would be invaluable in SLE research, longitudinal observational studies in population-based samples and long-term outcome assessments in clinical trials. Las siguientes preguntas nos ayudarán a comprender como el lupus lo ha afectado. No se preocupe si hay algunos términos médicos que Ud. no comprende. Eso generalmente quiere decir que Ud. no tiene el problema que le estamos preguntando. Sólo le ha de tomar alrededor de cinco minutos el completar este cuestionario.
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Indice de Evaluación de Lupus
Validation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al. 40) ¿Alguna vez ha tenido cirugía para remover parte de sus intestinos (no el estómago), el bazo, el hígado o la vesícula? 39) ¿Alguna vez un médico le ha dicho que Ud. ha tenido uno de los siguientes problemas: falta de circulación en sus intestinos (insuficiencia mesentérica), inflamación alrededor de los intestinos (peritonitis crónica), o una "torcedura" en sus intestinos?
38) ¿Alguna vez un médico le ha dicho que Ud. ha tenido un problema con el páncreas (no diabetes) que requiere tratamiento con enzimas de reemplazo? 37) ¿Alguna vez ha tenido cirugía en su estómago o esófago (tubo alimenticio)?
Estómago e Intestinos
36) ¿Alguna vez un médico le ha dicho que Ud. ha tenido hinchazón persistente en las piernas que es debido a problemas con sus venas (no venas varicosas)?
35) ¿Alguna vez un médico le ha dicho que Ud. ha tenido un coágulo o trombosis en la pierna que no esté asociado con hinchazón o ulceraciones (heridas abiertas o llagas) en la piel? 34) ¿Ha perdido uno de sus dedos de las manos o de los pies, un brazo o una pierna sin que haya tenido un accidente (gangrena)?
Si la respuesta es SI, ¿ha perdido más de un dedo, brazo o pierna que no haya sido por un accidente?
33) ¿Ha perdido la punta de uno de sus dedos sin que haya tenido un accidente (gangrena)?
31) ¿Por más de 6 meses ha tenido que detenerse cuando camina más que una distancia corta debido a dolor y calambres en las pantorrillas (piernas)?
32) ¿Fue diagnosticado por un médico de tener "claudicación" o "claudicación intermitente"? 
Músculos y Huesos
Validation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al. 4) Alguma vez teve um problema sério de saúde mental como psicose, esquizofrenia ou psicose por coticóides que durasse mais de 6 meses?
3) Alguma vez teve problemas sérios de memória, concentração ou dificuldade em falar, escrever ou resolver problemas de matemática que durasse mais de 6 meses? 17+  16  15  14  13  12  11  10  9  8  7  6  5  4  3 45) Você tem artrite nas suas mãos e seu médico(a) diz que os raios X mostram erosões/porose nos ossos?
NÃO SIM
Cérebro e Sistema Nervoso 2) Alguma vez um(a) médico ou oftalmologista lhe disse que tem um problema na retina que afecta a visão? Olhos 1) Alguma vez um(a) médico(a) ou oftalmologista lhe disse que tem catarata? Estas perguntas ajudar-nos-ão a entender melhor como o lupus o afectou. Não se preocupe caso existam alguns termos médicos que não entenda. Em princípio isto significa que não tem o problema que estamos a perguntar. Demora aproximadamente 5 minutos a completar este questionário. Instruções: EstasValidation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al.Validation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al.
Pós-graduação ou outro ---------Escola primária -------------Escola secundária----------
Pós-graduação ou outro ---------Escola primária -------------Escola secundária----------Universidade ----
NÃO
Instruções: Estas perguntas referem-se somente a problemas que apareceram depois do começo do lúpus. SOMENTE marque SIM se o problema apareceu depois do começo do LÚPUS. Se não for o caso, ou se isso não se aplicar a você, responda NÃO.
Músculos e ossos SIM
Validation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al.
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Draft 18) Vous a-t-on dit que vous aviez du tissu cicatriciel (fibrose) dans l'espace entourant les poumons (« fibrose pleurale »)?
19) Vous a-t-on dit que votre diaphragme ne bougeait pas bien ce qui causait de l'essoufflement (« atrophie pulmonaire »)? 20) Vous a-t-on dit que vous aviez un caillot de sang dans les poumons (embolie pulmonaire)? 21) Avez-vous subi une chirurgie des poumons pour une autre raison que le cancer? 17) Vous a-t-on dit que vous aviez des tissus fibreux (fibrose ou tissu cicatriciel) dans les poumons (« fibrose pulmonaire » ou « maladie pulmonaire interstitielle »)? Validation of some non-English versions of the Lupus Damage Index questionnaire BA Pons-Estel et al.
